Lakefront Biotherapeutics (LKFT) Receivables - Net (2013 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Receivables - Net for 13 consecutive years, with $25.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Receivables - Net fell 52.7% year-over-year to $25.4 million; the TTM figure through Mar 2026 stood at $25.4 million (down 52.7% YoY), while the FY2025 annual figure was $24.1 million, down 52.49% from the prior year.
• Receivables - Net rose to $25.4 million in Q1 2026 per LKFT's latest filing, from $24.1 million in the prior quarter.
• Across five years, Receivables - Net topped out at $69.2 million in Q1 2022 and bottomed at $24.1 million in Q4 2025.
• Historically, Receivables - Net has averaged $47.4 million across 5 years, with a median of $50.7 million in 2024.
• Annual changes were most pronounced in 2022 — Receivables - Net tumbled 67.61% — and 2024, when it surged 65.74%.
• Lakefront Biotherapeutics' Receivables - Net stood at $41.2 million in 2022, then declined by 25.79% to $30.6 million in 2023, then soared by 65.74% to $50.7 million in 2024, then tumbled by 52.49% to $24.1 million in 2025, then advanced by 5.59% to $25.4 million in 2026.
• Business Quant data shows LKFT's Receivables - Net at $25.4 million in Q1 2026, $24.1 million in Q4 2025, and $53.0 million in Q3 2025.